The EuroLVD registry was endorsed by the E-AHPBA and was initiated by:
Emmanuel Melloul, MD, FEBS (HPB),
Lausanne, Switzerland
Alban Denys, MD,
Lausanne, Switzerland
Nicolas Demartines, MD, FACS, FRCS,
Lausanne, Switzerland
Emmanuel Melloul, MD, FEBS (HPB),
Lausanne, Switzerland
Alban Denys, MD,
Lausanne, Switzerland
Nicolas Demartines, MD, FACS, FRCS,
Lausanne, Switzerland
Dr Rafael Duran and Prof. Alban Denys Lausanne (Switzerland)
Recently different research groups described sequential, ipsilateral hepatic vein embolization (HVE) after portal vein embolization (PVE) in human. They showed that preoperative sequential PVE and HVE seem to be safe and effective in facilitating contralateral liver regeneration.
However, in these studies, the increase in future remnant liver (FRL) could have been attributed wrongly to an ongoing hypertrophy caused by PVE alone. Nevertheless, these findings prompted the idea that simultaneous PVE and HVE could result in a greater hypertrophy response than PVE alone.
This technique named ipsilateral liver venous deprivation (LVD) has been described by Guiu et al. and appeared to be safe.
In addition, a recent study by Kobayashi et al. (Surgery 2020) in Switzerland confirmed the superiority of LVD over PVE alone to induce faster hypertrophy of the future remnant liver.
Several groups worldwide have now used this technique. For a more systematic exploration of this technique, randomized controlled trials of multiple centers and registries of cases are paramount to confirm the efficiency of LVD compared to other techniques such as PVE or Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS), the latter being associated with severe morbidity and mortality.
scroll back